Ormundo, L.F.; Barreto, C.T.; Tsuruta, L.R. Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections. Viruses2023, 15, 2177.
Ormundo, L.F.; Barreto, C.T.; Tsuruta, L.R. Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections. Viruses 2023, 15, 2177.
Ormundo, L.F.; Barreto, C.T.; Tsuruta, L.R. Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections. Viruses2023, 15, 2177.
Ormundo, L.F.; Barreto, C.T.; Tsuruta, L.R. Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections. Viruses 2023, 15, 2177.
Abstract
Antibody-based passive immunotherapy has been used effectively in the therapy and prophylaxis of infectious diseases. Outbreaks of the emerging viral infections from arthropod-borne viruses (arboviruses) represent a global public health problem due to the rapid spread and urge actions and treatment of the infected individuals to combat them. Preparedness in advance developing antivirals and studies related to the epidemiology could protect us from damages and losses. Immunotherapy based on monoclonal antibodies (mAbs) has shown to be very specific to combat infectious diseases and several illnesses. Recent advances in the mAb discovery techniques allowed the development and approval of a wide number of therapeutic mAbs. This review focuses on the technological approaches available to select neutralizing mAbs for emerging arbovirus infections and outstanding strategies to obtain highly effective and potent mAbs. The characteristics of mAbs developed as prophylactic and therapeutic antiviral agents for the dengue, Zika, chikungunya and West Nile virus are presented, as well as the protective effect verified in animal model studies.
Biology and Life Sciences, Biology and Biotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
